Hilde Fure

Hilde Fure

Auto-generated profile, based on publicly available information

Hilde Fure

Research Laboratory, Nordland Hospital, Prinsens Gate 164, 8092 Bodø, Norway

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002
Verified
Journal Article
Closed access
TMTom Eirik Mollnes
Tom Eirik Mollnes
OBOle-Lars Brekke
Ole-Lars Brekke
MFMichael Fung
Michael Fung
HFHilde Fure
Hilde Fure
DCDorte Christiansen
Dorte Christiansen
JLJohn D Lambris
John D Lambris

1 December 2015 in Critical Care
Verified
Journal Article
Open access
PDF file
ESEspen W. Skjeflo
Espen W. Skjeflo
CSCaroline Sagatun
Caroline Sagatun
KDKnut Dybwik
Knut Dybwik
SASturla Aam
Sturla Aam
SUSven H. Urving
Sven H. Urving
TMTom Mollnes
Tom Mollnes
Introduction: Sepsis is an exaggerated and dysfunctional immune response to infection. Activation of innate immunity recognition systems including complement and the Toll-like receptor family initiate this disproportionate inflammatory response. The aim of this study was to explore the effect of combined inhibition of the complement component C5 and the Toll-like receptor co-factor CD14 on survival, hemodynamic parameters and systemic inflammation including complement activation in a clinically relevant porcine model of polymicrobial sepsis. Methods: Norwegian landrace piglets (4 ± 0.5 kg) were blindly randomized to a treatment group (n = 12) receiving the C5 inhibitor coversin (OmCI) and anti-CD14 or to a positive control group (n = 12) receiving saline. Under anesthesia, sepsis was induced by a 2 cm cecal incision and the piglets were monitored in standard intensive care for 8 hours. Three sham piglets had a laparotomy without cecal incision or treatment. Complement activation was measured as sC5b-9 using enzyme immunoassay. Cytokines were measured with multiplex technology. Results: Combined C5 and CD14 inhibition significantly improved survival (p = 0.03). Nine piglets survived in the treatment group and four in the control group. The treatment group had significantly lower pulmonary artery pressure (p = 0.04) and ratio of pulmonary artery pressure to systemic artery pressure (p < 0.001). Plasma sC5b-9 levels were significantly lower in the treatment group (p < 0.001) and correlated significantly with mortality (p = 0.006). IL-8 and IL-10 were significantly (p < 0.05) lower in the treatment group. Conclusions: Combined inhibition of C5 and CD14 significantly improved survival, hemodynamic parameters and inflammation in a blinded, randomized trial of porcine polymicrobial sepsis.

1 September 2017 in Molecular Immunology
Verified
Journal Article
Closed access
Per NilssonPer Nilsson
Per Nilsson
CJChristina Johnson
Christina Johnson
SPSøren E. Pischke
Søren E. Pischke
HFHilde Fure
Hilde Fure
ALAnne Landsem
Anne Landsem
TMTom Mollnes
Tom Mollnes

1 September 2017 in Molecular Immunology
Verified
Journal Article
Closed access
ESElin Storjord
Elin Storjord
SAStella Airila-Månsson
Stella Airila-Månsson
KKKatarzyna Karlsen
Katarzyna Karlsen
MMMartin Madsen
Martin Madsen
JDJim André Dahl
Jim André Dahl
OBOle-Lars Brekke
Ole-Lars Brekke

1 September 2017 in Molecular Immunology
Verified
Journal Article
Closed access
DCDorte Christiansen
Dorte Christiansen
ESEspen Waage Skjeflo
Espen Waage Skjeflo
ALAnne Landsem
Anne Landsem
HFHilde Fure
Hilde Fure
JLJudith K. Ludviksen
Judith K. Ludviksen
TMTom Mollnes
Tom Mollnes

1 September 2017 in Molecular Immunology
Verified
Journal Article
Closed access
BKBård O. Karlsen
Bård O. Karlsen
HFHilde Fure
Hilde Fure
ALAnne Landsem
Anne Landsem
SJSteinar Daae Johansen
Steinar Daae Johansen
TMTom Mollnes
Tom Mollnes
OBOle-Lars Brekke
Ole-Lars Brekke